DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4c38wt/protein) has announced the addition of the "Global Protein Engineering Technologies Market" report to their offering.
The global protein engineering technologies market report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).
Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.
The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.
The global protein engineering market is expected to grow at a CAGR of 10.9%; this growth is majorly fuelled by monoclonal antibodies, which is the fastest growing segment in therapeutics. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Diagnostics is another segment in focus; monoclonal antibodies are being used extensively in diagnostics and in assays for research.
The report also profiles leading participants of the industry with their recent developments and other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).
Scope of the Report
Global Protein engineering, by Technology
- Sequence modification
- Glycosylation
- Pegylation
- Display technologies
- Humanization technology
- Hybrid technology
- Transgenic mice
Global Protein engineering, by Product
- mAb
- Insulin
- Others
- EPO
- Diagnostics
- Research
Geographic Analysis
- North America
- U.S.
- Canada
- Europe
- U.K.
- France
- Germany
- Italy
- Asia
- Indonesia
- India
- China
- South Korea
- Rest of the World (RoW)
- Japan
- Australia
For more information visit http://www.researchandmarkets.com/research/4c38wt/protein
